Prevention of AIDS dementia by HAART does not depend on cerebrospinal fluid drug penetrance

AIDS Research and Human Retroviruses

Volumn 20, Issue 5, 2004, Pages 483-491

  Evers, Stefan ^a,b   Rahmann, Alexandra ^a   Schwaag, Sonja ^a   Frese, Achim ^a   Reichelt, Doris ^a   Husstedt, Ingo W ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG PENETRATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INTERMETHOD COMPARISON; LATENT PERIOD; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RESPONSE TIME; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

EID: 2642577455     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922204323087723     Document Type: Article

References (66)

1. Brew BJ: AIDS dementia complex. Neurol Clin 1999;17:861-881.
2. Langford D, and Masliah E: Crosstalk between components of the blood brain barrier and cells of the CNS in microglial activation in AIDS. Brain Pathol 2001;11:306-312.
3. Wesselingh SL and Thompson KA: Immunopathogenesis of HIV-associated dementia. Curr Opin Neurol 2001;14:375-379.
4. Gartner S and Liu Y: Insights into the role of immune activation in HIV neuropathogenesis. J Neurovirol 2002;8:69-75.
5. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, and Brew BJ: Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999;13:1249-1253.
6. Childs EA, Lyles RH, Seines OA, et al.: Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999;52:607-613.
7. Garcia F, Niebla G, Romeu J, et al.: Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: Support for the hypothesis of local virus replication. AIDS 1999;13:1491-1496.
8. Sacktor N, Lyles RH, Skolasky R, et al.: HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study 1990-1998. Neurology 2001;56:257-260.
9. Ho DD, Bredesen DE, Vinters HV, and Daar ES: The acquired immuno-deficiency syndrome (AIDS) dementia complex. Ann Intern Med 1989;111:400-410.
10. McArthur JC, Sacktor N, and Seines O: Human immunodeficiency virus-associated dementia. Semin Neurol 1999;19:129-150.
11. Portegies P, de Gans J, Lange JMA, et al.: Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. Br Med J 1989;299:819-821.
12. Von Giesen HJ, Hefter H, Jablonowski H, and Arendt G: HAART is neuroprophylactic in HIV-1 infection. J Acquir Immune Defic Syndr 2000;23:380-385.
13. Messenheimer JA, Robertson KR, Wilkins JW, Kalkowski JC, and Hall CD: Event-related potentials in human immunodeficiency virus infection. Arch Neurol 1992;49:396-400.
14. Jabbari B, Coats M, Salazar A, Martin A, Scherokman B, and Laws WA: Longitudinal study of EEG and evoked potentials in neurologically asymptomatic HIV subjects. Electroencephalogr Clin Neurophysiol 1993;86:145-151.
15. Ragazzoni A, Grippo AS, Ghidini P, et al.: Electrophysiological study of neurologically asymptomatic HIV1 seropositive patients. Acta Neurol Scand 1993;87:47-51.
16. Connolly S, Manji H, McAllister RH, et al.: Long-latency event-related potentials in asymptomatic human immunodeficiency virus type 1 infection. Ann Neurol 1994;35:189-196.
17. Evers S, Grotemeyer KH, Reichelt D, Lüttmann S, and Husstedt IW: Impact of antiretroviral treatment on AIDS dementia: A longitudinal prospective event-related potential study. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:143-148.
18. Aznar-Bueno C, Abad-Alegria F, and Amiguet JA: Early detection of neurophysiological abnormalities in infection by human immunodeficiency virus. Clin Electroencephalogr 2000;31:116-121.
19. Galicia O, Sanchez-Alavez M, Diaz-Ruiz O, et al.: HIV-derived protein gp120 suppresses P3 potential in rats: Potential implications in HIV-associated dementia. Neuroreport 2000;11:1351-1355.
20. Polich J, Ilan A, Poceta JS, Mitler MM, and Darko DF: Neuroelectric assessment of HIV: EEG, ERP, and viral load. Int J Psychophysiol 2000;38:97-108.
21. Goodwin GM, Chiswick A, Egan V, St Clair D, and Brettle RP: The Edinburgh cohort of HIV positive drug users: Auditory event-related potentials show progressive slowing in patients with CDC stage IV disease. AIDS 1990;4:1243-1250.
22. Grotemeyer KH, Husstedt IW, Bründermann H, Busch H, Schlake HP, and Zidek W: Event-related potentials in HIV-infected outpatients. AIDS Res Hum Retroviruses 1991;7:629-635.
23. Ollo C, Johnson R, and Grafman J: Signs of cognitive change in HIV disease: An event-related brain potential study. Neurology 1991;41:209-215.
24. Coburn KL, Moore NC, Katner HP, Tucker KA, Pritchard WS, and Duke DW: HIV and the brain: Evidence of early involvement and progressive damage. Neuroreport 1992;3:539-541.
25. Arendt G, Hefter H, Nelles HW, Hilperath F, and Strohmeyer G: Age-dependent decline in cognitive information processing of HIV positive individuals detected by event-related recordings. J Neurol Sci 1993;115:223-229.
26. Baldeweg T, Gruzelier JH, Catalan J, et al.: Auditory and visual event-related potentials in a controlled investigation of HIV-infection. Electroencephalogr Clin Neurophysiol 1993;88:356-368.
27. Baldeweg T, Riccio M, Gruzelier J, et al.: Neurophysiological evaluation of zidovudine in asymptomatic HIV-1 infection: A longitudinal placebo-controlled study. J Neurol Sci 1995;132:162-169.
28. Fein G, Biggins CA, and MacKay S: Delayed latency of the event-related brain potential P3a component in HIV disease. Arch Neurol 1995;52:1109-1118.
29. Evers S, Husstedt IW, Lüttmann S, Bauer B, and Grotemeyer KH: Event-related potentials in HIV infection. Arch Neurol 1996;53:715-716.
30. Tozzi V, Balestra P, Galgani S, et al.: Positive and sustained effects of highly active antiretroviral therapy on HIV-1 associated neurocognitive impairment. AIDS 1999;13:1889-1897.
31. Husstedt IW, Frohne L, Böckenholt S, et al.: Impact of highly active antiretroviral therapy on cognitive processing in HIV infection: Cross-sectional and longitudinal studies on event-related potentials. AIDS Res Hum Retroviruses 2002;18:485-490.
32. Polich J and Basho S: P3a and P3b auditory ERPs in HIV patients receiving anti-viral medication. Clin Electroencephalogr 2002;33:97-101.
33. Sacktor NC, Lyles RH, Skolasky RL, et al.: Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Neurology 1999;52:1640-1647.
34. Cohen RA, Boland R, Paul R, et al.: Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS 2001;15:341-345.
35. Deutsch R, Ellis RJ, McCutchen JA, Marcotte TD, Letendre S, Grant I, and the HNRC Group: Aids-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. AIDS 2001;15:1898-1899.
36. Stankoff B, Tourbah A, Suarez S, et al.: Clinical and spectroscopic improvement in HIV-associated cognitive impairment. Neurology 2001;56:112-115.
37. Starace F, Bartoli L, Aloisi MS, et al.: Cognitive and affective disorders associated to HIV infection in the HAART era: Findings from the NeurolICONA study. Cognitive impairment and depression in HIV/AIDS. Acta Psychiatr Scand 2002;106:20-26.
38. Sacktor N, McDermott MP, Marder K, et al.: HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002;8:136-142.
39. Tyler KL: Through a glass, darkly. Cerebrospinal fluid viral load measurements and the pathogenesis of human immunodeficiency virus infection of the central nervous system. Arch Neurol 2002;59:909-912.
40. Enzensberger W for the German Neuro-Aids study group (DNAA): Antiretroviral therapy (ART) from a neurological point of view. Eur J Med Res 1999;4:456-462.
41. Sacktor N, Tarwater PM, Skolasky RL, et al.: CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology 2001;57:542-544.
42. Dougherty RH, Skolasky RL, and McArthur JC: Progression of HIV-associated dementia treated with HAART. AIDS Read 2002;12:69-74.
43. Centers for Disease Control: 1993 revised classification system for HIV infection. MMWR 1992;41:1-19.
44. Enting RH, Hoetelmans R, Lange J, Burger DM, Beijnen JH, and Portegies P: Antiretroviral drugs and the central nervous system. AIDS 1998;12:1941-1955.
45. Foudraine NA, Hoetelmans RM, Lange JM, et al.: Cerebrospinal fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998;351:1547-1551.
46. Glynn SL and Yazdanian M: In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharmaceut Sci 1998;87:306-310.
47. Aweeka F, Jayewardene A, Staprans S, et al.: Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia. J Acquir Immune Defic Syndr Hum Retroviral 1999;20:39-43.
48. Tashima KT, Caliendo AM, Ahmad M, et al.: Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentration in HIV-1-infected patients receiving combination therapy. J Infect Dis 1999;180:862-864.
49. Zhou XJ, Havlir DV, Richman DD, et al.: Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 2000;14:2869-2876.
50. Gisolf EH, van Heeswijk R, Hoetelmans R, and Danner S: Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir. AIDS 2000;14:801-805.
51. Gisolf EH, Enting RH, Jurriaans S, et al.: Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine. AIDS 2000;14:1583-1589.
52. Van Praag R, Weverling GJ, Portegies P, et al.: Enhanced penetration of indinavir in cerebrospinal fluid and semen after addition of low-dose ritonavir. AIDS 2000;14:1187-1194.
53. Thomas SA, Bye A, and Segal MB: Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid. J Pharmacol Exp Ther 2001;298:947-953.
54. Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, and Lacarelle B: Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: Clinical correlations. HIV Clin Trials 2002;3:27-35.
55. Wynn HE, Brundage RC, and Fletcher CV: Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002;16:595-609.
56. Goodin D, Desmedt J, Maurer K, and Nuwer M: IFN recommended standards for long-latency auditory event-related potentials. Report of an IFCN committee. Electroencephalogr Clin Neurophysiol 1994;91:18-20.
57. Picton TW: The P300 wave of the human event-related potential. J Clin Neurophysiol 1992;9:456-479.
58. McClernon DR, Lanier R, Gartner S, et al.: HIV in the brain. RNA levels and patterns of zidovudine resistance. Neurology 2001;57:1396-1401.
59. Chang L, Ernst T, Leonido-Yee M, et al.: Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 1999;53:782-789.
60. Möller HE, Vermathen P, Lentschig MG, et al.: Metabolite characterization of AIDS dementia complex by spectroscopic imaging. J Magn Reson Imaging 1999;9:10-18.
61. Strelow LI, Janigro D, and Nelson JA: The blood-brain barrier and AIDS. Adv Virus Res 2001;56:355-388.
62. De Luca A, Ciancio BC, Larussa D, et al.: Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology 2002;59:342-347.
63. Carr A and Cooper DA: Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-1430.
64. Max B and Sherer R: Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 2000;30:S96-S116.
65. Brodt HR, Helm EB, and Kamps BS: AIDS 2000. Diagnostik und Therapie. Steinhäuser Verlag, Wuppertal, Germany, 2000.
66. Marra CM and Booss J: Does brain penetration of anti-HIV drugs matter? Sex Transm Infect 2000;76:1-2.